BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 4.7% Higher - Here's Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s stock price rose 4.7% during trading on Tuesday . The company traded as high as $7.89 and last traded at $7.87. Approximately 506,527 shares changed hands during trading, a decline of 83% from the average daily volume of 2,970,365 shares. The stock had previously closed at $7.52.

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities raised their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Finally, Barclays raised their price target on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an "equal weight" rating in a report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $14.17.

BioCryst Pharmaceuticals Price Performance

The company has a market cap of $1.64 billion, a P/E ratio of -7.43 and a beta of 1.88. The firm's 50-day moving average is $7.81 and its two-hundred day moving average is $6.72.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to the consensus estimate of $98.30 million. The business's quarterly revenue was up 34.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.24) earnings per share. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently made changes to their positions in BCRX. Deerfield Management Company L.P. Series C raised its position in shares of BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock valued at $50,279,000 after buying an additional 3,140,804 shares in the last quarter. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock valued at $106,405,000 after buying an additional 2,371,401 shares in the last quarter. Kynam Capital Management LP raised its position in shares of BioCryst Pharmaceuticals by 41.9% during the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company's stock valued at $33,160,000 after buying an additional 1,927,491 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of BioCryst Pharmaceuticals by 528.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company's stock valued at $6,874,000 after buying an additional 935,132 shares in the last quarter. Finally, Point72 Europe London LLP purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth about $1,654,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.